http://orcid.org/0000-0002-4816-7278
References
- Frangides CY, Koulouras V, Kouni SN, et al. Snake venom poisoning in Greece. Experiences with 147 cases. Eur J Intern Med. 2006;17:24–27.
- Lukšić B, Bradarić N, Prgomet S. Venomous snakebites in Southern Croatia. Coll Antropol. 2006;30:191–197.
- Karabuva S, Vrkić I, Brizić I, et al. Venomous snakebites in children in Southern Croatia. Toxicon. 2016;112:8–15.
- Latinović Z, Leonardi A, Šribar J, et al. Venomics of Vipera berus berus to explain differences in pathology elicited by Vipera ammodytes ammodytes envenomation: therapeutic implications. J Proteomics. 2016;146:34–47.
- Kurtović T, Brvar M, Grenc D, et al. A single dose of ViperfavTM may be inadequate for Vipera ammodytes snake bite: a case report and pharmacokinetic evaluation. Toxins. 2016;8(8):244.
- Casewell NR, Al-Abdulla I, Smith D, et al. Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb. Toxins. 2014;6:2471–2482.
- Lang Balija M, Vrdoljak A, Habjanec L, et al. The variability of Vipera ammodytes ammodytes venoms from Croatia biochemical properties and biological activity. Comp Biochem Physiol C. 2005;140:257–263.
- Control and regulation of snake venom immunoglobulins. WHO Guidelines for the production. Geneva: WHO Press; 2010. p. 19–29.
- Meier J, Adler C, Hössle P, et al. The influence of three drying procedures on some enzymatic activities of three viperidae snake venoms. Mem Inst Butantan. 1991;53:119–126.
- Lian NS, Pungerčar J, Križaj I, et al. Expression of fully active ammodytoxin A, a potent presynaptically neuro-toxic phospholipase A2, in Escherichia coli. FEBS Lett. 1993;334:55–59.
- Zhang Y, Huo M, Zhou J, et al. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306–314.
- Ludden TM, Beal SL, Sheiner LB. Comparison of the akaike information criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22:431–445.
- Boels D, Hamel JF, Bretaudeau Deguigne M, et al. European viper envenomings: assessment of Viperfav™ and other symptomatic treatments. Clin Toxicol. 2012;50:189–196.
- Jollivet V, Hamel JF, de Haro L, et al. European viper envenomation recorded by French poison control centers: a clinical assessment and management study. Toxicon. 2015;108:97–103.
- Križaj I. Ammodytoxin: a window into understanding presynaptic toxicity of secreted phospholipases A(2) and more. Toxicon. 2011;58:219–229.
- Halassy B, Habjanec L, Lang Balija M, et al. Ammodytoxin content of Vipera ammodytes ammodytes venom as a prognostic factor for venom immunogenicity. Comp Biochem Physiol C Toxicol Pharmacol. 2010;151:455–460.
- Halassy B, Brgles M, Habjanec L, et al. Intraspecies variability in Vipera ammodytes ammodytes venom related to its toxicity and immunogenic potential. Comp Biochem Physiol C Toxicol Pharmacol. 2011;153:223–230.
- Seifert SA, Boyer LV, Dart RC, et al. Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox envenomation treated with a Fab antivenom. Ann Emerg Med. 1997;30:49–53.
- Offerman SR, Barry JD, Schneir A, et al. Biphasic rattlesnake venom-induced thrombocytopenia. J Emerg Med. 2003;24:289–293.
- Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med. 2001;37:189–195.